Data Sheet (Cat.No.T2337)

TargetMol

BMS-303141

Chemical Properties



CAS No. : 943962-47-8

Formula: C19H15Cl2NO4S

Molecular Weight: 424.3

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	BMS-303141 is a potent ATP-citrate lyase (ACL) inhibitor (IC50: 0.13 uM, human recombinant ACL).
Targets(IC50)	ATP Citrate Lyase
In vitro	BMS-303141 shows inhibition of total lipid syntheses with an IC50 of 8 μM in HepG2 cells. BMS-303141 shows no cytotoxicity up to 50 lM under a cell-based Alamar Blue cytotoxicity assay, indicating the observed inhibition of lipid synthesis is not a result of compound-induced cytotoxicity[1].
In vivo	Chronic oral administration of BMS-303141 to mice on a high-fat diet reduces plasma cholesterol and triglycerides by approximately 20-30% and fasting plasma glucose by 30-50%. Continued treatment with BMS-303141 gradually inhibits weight gain and decreases adiposity without affecting food consumption. BMS-303141 displays an oral bioavailability of 55% and a relatively brief half-life of 2.1 hours[1].

Solubility Information

Solubility	DMSO: 247.5 mg/mL (583.31 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.3568 mL	11.7841 mL	23.5682 mL
5 mM	0.4714 mL	2.3568 mL	4.7136 mL
10 mM	0.2357 mL	1.1784 mL	2.3568 mL
50 mM	0.0471 mL	0.2357 mL	0.4714 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Li JJ, et al. 2-hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3208-11.

Tang C, Wang H, Guo L, et al.CpG-Conjugated Silver Nanoparticles as a Multifunctional Nanomedicine to Promote Macrophage Efferocytosis and Repolarization for Atherosclerosis Therapy.ACS Applied Materials & Interfaces.2023

Shi L, Chen H, Zhang Y, et al.SLC13A2 promotes hepatocyte metabolic remodeling and liver regeneration by enhancing de novo cholesterol biosynthesis.The EMBO Journal.2025: 1-22.